Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcturus Therapeutics Holdings (ARCT) Debt to Equity (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Debt to Equity for 7 consecutive years, with $0.06 as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Debt to Equity changed N/A year-over-year to $0.06, compared with a TTM value of $0.06 through Mar 2025, changed N/A, and an annual FY2022 reading of $0.22, down 18.86% over the prior year.
  • Debt to Equity was $0.06 for Q1 2025 at Arcturus Therapeutics Holdings, down from $0.07 in the prior quarter.
  • Across five years, Debt to Equity topped out at $0.41 in Q3 2022 and bottomed at $0.06 in Q1 2025.
  • Average Debt to Equity over 4 years is $0.23, with a median of $0.23 recorded in 2022.
  • The sharpest move saw Debt to Equity skyrocketed 626.46% in 2021, then plummeted 82.59% in 2023.
  • Year by year, Debt to Equity stood at $0.28 in 2021, then fell by 18.86% to $0.22 in 2022, then plummeted by 68.17% to $0.07 in 2023, then dropped by 10.14% to $0.06 in 2025.
  • Business Quant data shows Debt to Equity for ARCT at $0.06 in Q1 2025, $0.07 in Q3 2023, and $0.22 in Q4 2022.